HORMAD1 overexpression predicts response to anthracycline–cyclophosphamide and survival in triple‐negative breast cancers

Triple negative breast cancers (TNBCs) represent 15–20% of all breast cancers and are associated with higher recurrence and distant metastasis rate. Standard of care for early stage TNBC is anthracyclines combined with cyclophosphamide (AC) followed by taxanes, in the neo‐adjuvant or adjuvant settin...

Descripción completa

Detalles Bibliográficos
Autores principales: El‐Botty, Rania, Vacher, Sophie, Mainguené, Juliette, Briaux, Adrien, Ibadioune, Sabrina, Dahmani, Ahmed, Montaudon, Elodie, Nemati, Fariba, Huguet, Léa, Sourd, Laura, Morriset, Ludivine, Château‐Joubert, Sophie, Dubois, Thierry, Maire, Virginie, Lidereau, Rosette, Rapinat, Audrey, Gentien, David, Coussy, Florence, Bièche, Ivan, Marangoni, Elisabetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552896/
https://www.ncbi.nlm.nih.gov/pubmed/36852691
http://dx.doi.org/10.1002/1878-0261.13412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552896/
https://www.ncbi.nlm.nih.gov/pubmed/36852691
http://dx.doi.org/10.1002/1878-0261.13412

Ejemplares similares